

# Women's health

HRA Pharma was founded with the objective to improve the health and the quality of life of women worldwide. The company seeks to fulfill its mission by focusing its research, development and operational efforts on medical needs which are not adequately addressed by existing therapeutics.


### **PRODUCTS**

We currently have a marketed portfolio of six women's health pharmaceutical products and devices, which include:

- ellaOne® /ella® (ulipristal acetate, 30 mg, tablet), marketed in Europe and the United States since 2009 and 2010 respectively. In 2015, the European Commission has authorized ellaOne® to be accessible direct from pharmacies without the need for a prescription from a doctor.
- NorLevo® (levonorgestrel, I.5mg, tablet), HRA Pharma's first product, was launched in France in 1999. It was the first progestinonly emergency contraceptive pill to be approved in the Western world and to be granted a non-prescription status, making it broadly accessible.
- esmya  $^{\otimes}$ , a novel therapy for uterine fibroids, which are benign tumors of the uterus.

Our portfolio also includes treatments for genital herpes, vaginal restorative, derm healing and regular contraception.

### **HRA PHARMA QUICK FACTS**



#### **OUR PRODUCTS**

ellaOne<sup>®</sup>/ella<sup>®</sup>(ulipristal acetate)
NorLevo<sup>®</sup> (levonorgestrel)
esmya<sup>®</sup> (ulipristal acetate)
Clareva Gel<sup>TM</sup> (oxidised glycerol
triester)
Mona Lisa<sup>®</sup> (copper-IUD)
Cicatridine<sup>®</sup> (hyaluronic acid,
cream)
Cicatridine<sup>®</sup> (hyaluronic acid,
vaginal capsules)

## CURRENTLY TARGETED INDICATIONS

Emergency Contraception Gynecological diseases Sexuality Infectious diseases

# INDICATIONS IN THE PIPELINE

Regular contraception Incontinence

## INDICATIONS UNDER PROSPECTION

Fertility
Female Cancers
Menopause
Osteoporosis

#### **PARTNERING**

Our products are designed to enhance self-management of reproductive health needs and boost women's autonomy. We are always interested to hear from partners who wish to manufacture, distribute our products, to help us further develop our product candidates or to license-out their products.